Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,419
archived clinical trials in
Pulmonary

A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation
A Phase 3, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Status: Enrolling
Updated:  9/2/2015
mi
from
Brisbane,
A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation
A Phase 3, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Status: Enrolling
Updated: 9/2/2015
mi
from
Brisbane,
Click here to add this to my saved trials
Peripheral Blood Biomarkers in Idiopathic Interstitial Pneumonias
Genetics, Genomics, and Proteomics of Idiopathic Interstitial Pneumonias: Identification of Susceptibility Genes, Biomarkers, and Molecular Phenotyping
Status: Enrolling
Updated:  9/8/2015
National Jewish Health
mi
from
Denver, CO
Peripheral Blood Biomarkers in Idiopathic Interstitial Pneumonias
Genetics, Genomics, and Proteomics of Idiopathic Interstitial Pneumonias: Identification of Susceptibility Genes, Biomarkers, and Molecular Phenotyping
Status: Enrolling
Updated: 9/8/2015
National Jewish Health
mi
from
Denver, CO
Click here to add this to my saved trials
Peripheral Blood Biomarkers in Idiopathic Interstitial Pneumonias
Genetics, Genomics, and Proteomics of Idiopathic Interstitial Pneumonias: Identification of Susceptibility Genes, Biomarkers, and Molecular Phenotyping
Status: Enrolling
Updated:  9/8/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Peripheral Blood Biomarkers in Idiopathic Interstitial Pneumonias
Genetics, Genomics, and Proteomics of Idiopathic Interstitial Pneumonias: Identification of Susceptibility Genes, Biomarkers, and Molecular Phenotyping
Status: Enrolling
Updated: 9/8/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Stochastic Resonance Mattress (Physiological Interventions) and Biomarkers for Enhancing Neonatal Health
Stochastic Resonance Mattress (Physiological Interventions) and Biomarkers for Enhancing Neonatal Health
Status: Enrolling
Updated:  9/9/2015
Beth Israel Deaconness Medical Center
mi
from
Boston, MA
Stochastic Resonance Mattress (Physiological Interventions) and Biomarkers for Enhancing Neonatal Health
Stochastic Resonance Mattress (Physiological Interventions) and Biomarkers for Enhancing Neonatal Health
Status: Enrolling
Updated: 9/9/2015
Beth Israel Deaconness Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Promoting Adherence to Sleep Apnea Treatment Among Blacks With Metabolic Syndrome
Promoting Adherence to Sleep Apnea Treatment Through Health Education Among Blacks With Metabolic Syndrome
Status: Enrolling
Updated:  9/9/2015
New York University
mi
from
New York, NY
Promoting Adherence to Sleep Apnea Treatment Among Blacks With Metabolic Syndrome
Promoting Adherence to Sleep Apnea Treatment Through Health Education Among Blacks With Metabolic Syndrome
Status: Enrolling
Updated: 9/9/2015
New York University
mi
from
New York, NY
Click here to add this to my saved trials
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated:  9/9/2015
UAB Division of Pulmonary
mi
from
Birmingham, AL
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated: 9/9/2015
UAB Division of Pulmonary
mi
from
Birmingham, AL
Click here to add this to my saved trials
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated:  9/9/2015
Pulmonary Associates, PA
mi
from
Phoenix, AZ
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated: 9/9/2015
Pulmonary Associates, PA
mi
from
Phoenix, AZ
Click here to add this to my saved trials
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated:  9/9/2015
Mayo Clinic
mi
from
Scottsdale, AZ
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated: 9/9/2015
Mayo Clinic
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated:  9/9/2015
USC/University Hospital
mi
from
Los Angeles, CA
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated: 9/9/2015
USC/University Hospital
mi
from
Los Angeles, CA
Click here to add this to my saved trials
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated:  9/9/2015
UCLA Division of Pulmonary and Critical Care
mi
from
Los Angeles, CA
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated: 9/9/2015
UCLA Division of Pulmonary and Critical Care
mi
from
Los Angeles, CA
Click here to add this to my saved trials
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated:  9/9/2015
UC Davis University of California
mi
from
Sacramento, CA
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated: 9/9/2015
UC Davis University of California
mi
from
Sacramento, CA
Click here to add this to my saved trials
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated:  9/9/2015
UCSD Medical Center
mi
from
San Diego, CA
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated: 9/9/2015
UCSD Medical Center
mi
from
San Diego, CA
Click here to add this to my saved trials
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated:  9/9/2015
UCSF-Interstitial Lung Disease Center
mi
from
San Francisco, CA
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated: 9/9/2015
UCSF-Interstitial Lung Disease Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated:  9/9/2015
Pulmonary and Critical Care Medicine-Stanford University Medical Center
mi
from
Stanford, CA
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated: 9/9/2015
Pulmonary and Critical Care Medicine-Stanford University Medical Center
mi
from
Stanford, CA
Click here to add this to my saved trials
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated:  9/9/2015
National Jewish Medical and Research Center
mi
from
Denver, CO
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated: 9/9/2015
National Jewish Medical and Research Center
mi
from
Denver, CO
Click here to add this to my saved trials
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated:  9/9/2015
Yale University School of Medicine-Dept of Internal Med-Pulmonary & Critical Care
mi
from
New Haven, CT
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated: 9/9/2015
Yale University School of Medicine-Dept of Internal Med-Pulmonary & Critical Care
mi
from
New Haven, CT
Click here to add this to my saved trials
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated:  9/9/2015
PAB Clinical Research
mi
from
Brandon, FL
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated: 9/9/2015
PAB Clinical Research
mi
from
Brandon, FL
Click here to add this to my saved trials
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated:  9/9/2015
Emory University
mi
from
Atlanta, GA
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated: 9/9/2015
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated:  9/9/2015
University of Chicago - Section of Pulmonary, Dept of Medicine, Respiratory Clinical Research
mi
from
Chicago, IL
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated: 9/9/2015
University of Chicago - Section of Pulmonary, Dept of Medicine, Respiratory Clinical Research
mi
from
Chicago, IL
Click here to add this to my saved trials
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated:  9/9/2015
Consultants in Pulmonary Medicine
mi
from
Olathe, KA
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated: 9/9/2015
Consultants in Pulmonary Medicine
mi
from
Olathe, KA
Click here to add this to my saved trials
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated:  9/9/2015
Wichita Clinic
mi
from
Wichita, KA
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated: 9/9/2015
Wichita Clinic
mi
from
Wichita, KA
Click here to add this to my saved trials
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated:  9/9/2015
Boston University School of Medicine
mi
from
Boston, MA
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated: 9/9/2015
Boston University School of Medicine
mi
from
Boston, MA
Click here to add this to my saved trials
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated:  9/9/2015
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated: 9/9/2015
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated:  9/9/2015
Univ of Minnesota
mi
from
Minneapolis, MN
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated: 9/9/2015
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated:  9/9/2015
The Mayo Clinic
mi
from
Rochester, MN
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated: 9/9/2015
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated:  9/9/2015
St. Luke's Medical Group, Cardio-Pulmonary Research
mi
from
Chesterfield, MO
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated: 9/9/2015
St. Luke's Medical Group, Cardio-Pulmonary Research
mi
from
Chesterfield, MO
Click here to add this to my saved trials
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated:  9/9/2015
Pulmonary and Allergy Associates
mi
from
Summit, NJ
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated: 9/9/2015
Pulmonary and Allergy Associates
mi
from
Summit, NJ
Click here to add this to my saved trials
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated:  9/9/2015
Mount Sinai School of Medicine
mi
from
New York, NY
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated: 9/9/2015
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated:  9/9/2015
Highland Hospital - Pulmonary Department
mi
from
Rochester, NY
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated: 9/9/2015
Highland Hospital - Pulmonary Department
mi
from
Rochester, NY
Click here to add this to my saved trials
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated:  9/9/2015
Duke Univ Med Ctr
mi
from
Durham, NC
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated: 9/9/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated:  9/9/2015
University of Cincinnati
mi
from
Cincinnati, OH
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated: 9/9/2015
University of Cincinnati
mi
from
Cincinnati, OH
Click here to add this to my saved trials
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated:  9/9/2015
Cleveland Clinic Foundation
mi
from
Cleveland, OH
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated: 9/9/2015
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated:  9/9/2015
The University of Pennsylvania Medical Center
mi
from
Philadelphia, PA
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated: 9/9/2015
The University of Pennsylvania Medical Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated:  9/9/2015
Temple University Hospital
mi
from
Philadelphia, PA
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated: 9/9/2015
Temple University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated:  9/9/2015
Medical University of South Carolina
mi
from
Charleston, SC
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated: 9/9/2015
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated:  9/9/2015
Vanderbilt Medical Center - IPF Center
mi
from
Nashville, TN
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated: 9/9/2015
Vanderbilt Medical Center - IPF Center
mi
from
Nashville, TN
Click here to add this to my saved trials
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated:  9/9/2015
University of Texas-Southwestern Dallas-Div. of Pulm & Critical Care Unit
mi
from
Dallas, TX
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated: 9/9/2015
University of Texas-Southwestern Dallas-Div. of Pulm & Critical Care Unit
mi
from
Dallas, TX
Click here to add this to my saved trials
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated:  9/9/2015
Baylor College of Medicine
mi
from
Houston, TX
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated: 9/9/2015
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated:  9/9/2015
University of Utah
mi
from
Salt Lake City, UT
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated: 9/9/2015
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated:  9/9/2015
Vermont Lung Center
mi
from
Colchester, VT
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated: 9/9/2015
Vermont Lung Center
mi
from
Colchester, VT
Click here to add this to my saved trials
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated:  9/9/2015
University of Virginia - Div. of Pulmonary & Critical Care
mi
from
Charlottesville, VA
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated: 9/9/2015
University of Virginia - Div. of Pulmonary & Critical Care
mi
from
Charlottesville, VA
Click here to add this to my saved trials
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated:  9/9/2015
Inova Heart and Vascular Institute
mi
from
Falls Church, VA
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated: 9/9/2015
Inova Heart and Vascular Institute
mi
from
Falls Church, VA
Click here to add this to my saved trials
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated:  9/9/2015
University of Washington Medical Center
mi
from
Seattle, WA
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated: 9/9/2015
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated:  9/9/2015
University of Wisconsin-Madison
mi
from
Madison, WI
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated: 9/9/2015
University of Wisconsin-Madison
mi
from
Madison, WI
Click here to add this to my saved trials
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated:  9/9/2015
St. Vincent's Public Hospital, Lung Transplantation & Respiratory Medicine
mi
from
Darlinghurst,
BUILD 3: Bosentan Use in Interstitial Lung Disease
Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
Status: Enrolling
Updated: 9/9/2015
St. Vincent's Public Hospital, Lung Transplantation & Respiratory Medicine
mi
from
Darlinghurst,
Click here to add this to my saved trials
Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443
Open-Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321 (NCT00391443)
Status: Enrolling
Updated:  9/9/2015
UAB Division of Pulmonary
mi
from
Birmingham, AL
Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443
Open-Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321 (NCT00391443)
Status: Enrolling
Updated: 9/9/2015
UAB Division of Pulmonary
mi
from
Birmingham, AL
Click here to add this to my saved trials
Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443
Open-Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321 (NCT00391443)
Status: Enrolling
Updated:  9/9/2015
Mayo Clinic
mi
from
Scottsdale, AZ
Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443
Open-Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321 (NCT00391443)
Status: Enrolling
Updated: 9/9/2015
Mayo Clinic
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443
Open-Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321 (NCT00391443)
Status: Enrolling
Updated:  9/9/2015
UCLA- Division of Pulmonary & Critcal Care
mi
from
Los Angeles, CA
Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443
Open-Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321 (NCT00391443)
Status: Enrolling
Updated: 9/9/2015
UCLA- Division of Pulmonary & Critcal Care
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443
Open-Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321 (NCT00391443)
Status: Enrolling
Updated:  9/9/2015
UCSD Medical Center
mi
from
San Diego, CA
Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443
Open-Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321 (NCT00391443)
Status: Enrolling
Updated: 9/9/2015
UCSD Medical Center
mi
from
San Diego, CA
Click here to add this to my saved trials
Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443
Open-Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321 (NCT00391443)
Status: Enrolling
Updated:  9/9/2015
USCF-Interstitial Lung Disease Center
mi
from
San Francisco, CA
Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443
Open-Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321 (NCT00391443)
Status: Enrolling
Updated: 9/9/2015
USCF-Interstitial Lung Disease Center
mi
from
San Francisco, CA
Click here to add this to my saved trials